Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Aug 31, 2021 11:53am
213 Views
Post# 33787970

RE:Excluding the Pending Study 2 Data on 27 patients

RE:Excluding the Pending Study 2 Data on 27 patients

It looks like the first bar graph at 90 days includes only patients 13-24  Hence 1 patient is 8.3%.  So 33% CR is 4 out of 6 plus one out of 6 is PR and one out of 6 was NR patient who passed away but had a 95% chance of being CR as per negative predictive value of a negative urine cytology.  IMO  so 67%-100% CR potential based on those 6 patients at 90 days.  Afterwards 180 days on it looks like graphs include those 12 patients plus the outcome of 3 from the 1st set of 12 who received an optimized maintenance treatment at 6 months mark ( after August 2020 optimization)  All IMO do your DD, but this is very very encouraging to me.


cashascars wrote: Here is my math when you exclude the Pending and only include the examined patients at each interval.

90 days---- 61.9% CR+PR
180 days---55.5% CR+PR
270 days---41.2% CR+PR
360 days---37.5% CR+PR
450 days----28.6% CR+PR

And as you know the numbers will only get better because the original 12 undertreated 
are incuded in this calculation.

These are great numbers and for the simplicity of the procedure we are on our way to becomeing the gold standard baby!
All this is in my own head and that could be the only problem.
cashascars

 

<< Previous
Bullboard Posts
Next >>